SCHEDULE: BlackRock Discloses 1.8% Passive Stake in TScan Therapeutics
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 1.8% beneficial ownership stake in TScan Therapeutics, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 958,373 shares of TScan Therapeutics, Inc. Common Stock.
- This ownership represents 1.8% of the total outstanding shares of TScan Therapeutics, Inc.
- BlackRock holds sole voting power over 955,843 shares and sole dispositive power over 958,373 shares.
- The filing is an Amendment No. 1 to a previous Schedule 13G, indicating a change in their reported ownership.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of TScan Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment as it does not discuss company performance, strategy, or future prospects.
Positives
- NA
Negatives
- NA
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, which could be a risk for investors seeking activist engagement from large shareholders.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding TScan Therapeutics, Inc.'s future performance or strategic outlook.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing indicates a passive investment by a major institutional asset manager, BlackRock, in a biotechnology company, TScan Therapeutics. Such disclosures are routine for large investment firms that manage significant portfolios across various industries, reflecting their broad market exposure rather than a specific strategic move related to TScan's industry trends.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Policy/Authorization Update | BlackRock, Inc. executed a new Power of Attorney, effective January 21, 2025, revoking a prior one dated April 30, 2023. This new power of attorney authorizes specific individuals (Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, and Brenda Schulz) to execute and file various ownership and control-person reporting documents on behalf of BlackRock and its subsidiaries. | 2025-01-21 | This change streamlines BlackRock's internal compliance processes for SEC and other regulatory filings, ensuring authorized personnel can efficiently manage disclosure requirements. It does not directly impact TScan Therapeutics' corporate governance. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming BlackRock's investment in TScan Therapeutics without intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously revoked Power of Attorney by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney executed by BlackRock, Inc. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-07-16 | Date the Schedule 13G statement was signed by BlackRock, Inc. |
Keywords
BlackRock, TScan Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.